Jointly Sponsored by The Postgraduate Institute for Medicine and ViralEd, Inc..
About the Program
Program Overview
The treatment of people with HIV infection is rapidly and constantly progressing as research that is published and presented at major scientific congresses leads to the use of new drugs and clinical strategies. However, clinicians are not always able to keep up with this flood of new information, and some clinical decisions must be made based on research that is open to interpretation. To address this problem, this program will have a panel of experts present and debate the studies and data that support different clinical options and strategies, which will allow the audience to assess the relative merits of various positions.
This program will use patient case vignettes to set up debates on the most pressing and controversial issues pertaining to treatment of HIV and show how national thought leaders approach the difficult choices involved. The outcome of this program will be that clinicians who treat patients with HIV infection will have an improved understanding of the various data supporting different views of complex clinical controversies and the enhanced knowledge and confidence needed to improve care and outcomes in patients with HIV infection.
Back to Top
Program Agenda
-
Welcome and Introduction (John Bartlett, MD)
-
Debate 1: When to Start: The Earlier, the Better (Paul Sax, MD vs. Chuck Hicks, MD)
-
Debate 2: What to Start: Efavirenz/tenofovir/emtricitabine Tablet Is Still King (Trevor Hawkins, MD vs. Judith Feinberg, MD)
-
Debate 3: PrEP: The Time Is Now (Ian Frank, MD vs. David Wohl, MD)
-
Closing Remarks (John Bartlett, MD)
All debates to feature rebuttal by Joe Eron, MD and Calvin Cohen, MD followed by panel and audience discussion.
Back to Top
Target Audience
This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the treatment and management of patients with HIV infection.
Back to Top
Learning Objectives
Upon completion of the program, participants should be able to:
- Explain when it is appropriate to start ARV therapy;
- Discuss various options for initiating ARV therapy in treatment-naïve HIV-infected patients;
- Identify the use of new or novel ARV therapies and regimens;
- Describe sequencing and switching ARVs in various patient scenarios;
- Appraise the use of PrEP to prevent HIV infection in at-risk populations.
Release Date: November 18, 2010
Expiration Date: November 18, 2011
Estimated time to complete this On-Demand Web Symposium: 2 hours
Media: Internet
Back to Top
Course Directors
|
Calvin J. Cohen, MD, MS
Research Director, CRI New England
Clinical Instructor, Harvard Medical School
Boston, Massachusetts
|
|
Joseph Eron, MD
Professor,
University of North Carolina School of Medicine
Chapel Hill, North Carolina
|
|
John Bartlett, MD
Professor of Medicine,
Johns Hopkins School of Medicine
Baltimore, Maryland
|
Back to Top
Faculty
Ian Frank, MD
Professor of Medicine,
Director, Antiretroviral Clinical Research
University of Pennsylvania
Philadelphia, Pennsylvania |
Judith Feinberg, MD
Professor of Medicine,
Associate Chair of Medicine for Faculty Development,
University of Cincinnati College of Medicine
Cincinnati, Ohio
|
|
Charles Hicks, MD
Professor of Medicine,
Department of Infectious Diseases
Duke University Medical Center
Durham, North Carolina |
Trevor Hawkins, MD
Associate Clinical Professor,
Department of Family Practice
University of New Mexico
Medical Director, Southwest C.A.R.E.
Santa Fe, New Mexico
|
|
David Wohl, MD
Associate Professor of Medicine,
Division of Infectious Diseases,
The University of North Carolina School of Medicine
Co-Director of HIV Services,
North Carolina Department of Corrections
Chapel Hill, North Carolina |
Paul Sax, MD
Clinical Director,
Brigham and Women's Division of
Infectious Diseases and HIV Program
Associate Professor of Medicine,
Harvard Medical School
Boston, Massachusetts
|
Edwin DeJesus, MD
Medical Director,
Orlando Immunology Center
Orlando, Florida
|
|
|
|
|
|
Back to Top
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Back to Top
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Back to Top
Disclosure of Conflicts of Interest
The Postgraduate Institute for Medicine assesses conflicts of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Postgraduate Institute for Medicine is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
John Bartlett, MD
- Consulting Fees: Mediscape; UpToDate; Epocates
|
Calvin Cohen, MD
- Consulting Fees: Gilead; Bristol-Myers Squibb; Merck; Janssen; ViiV
- Grants/Research: Gilead; Bristol-Myers Squibb; Merck; Janssen; ViiV
|
Edwin DeJesus, MD
- Contracted Research: Abbott; Achillion; Avexa; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Hoffman LaRoche; Merck; Pfizer; Schering Plough; Taimed; Tobira; Tibotec; Vertex
- Consulting Fees/Speakers Bureau: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Tibotec
|
Joseph Eron, MD
- Research Grants to the University of North Carolina (PI): Merck; GlaxoSmithKline/ViiV; Tobira; TaiMed
- Consulting Fees: Argos; Gilead; GlaxoSmithKline/ViiV; Merck; Tibotec; Tobira; BMS
|
Judith Feinberg, MD
- Contracted Research: BMS; Boehringer Ingelheim; GSK/ViiV; Janssen; Tobira; Roche
- Speaker Bureau: BMS; GKS/ViiV; Janssen; Merck
- Consulting Fees: Janssen; GSK/ViiV
|
Ian Frank, MD
- Contracted Research: GlaxoSmithKline
- Consulting Fees: Gilead; Tibotec
|
Trevor Hawkins, MD
- Contracted Research: Gilead; GSK; Janssen; Vertex; Salix
- Speakers Bureau: BMS; Gilead; Janssen; Merck; Vertex
- Consulting Fees: Gilead; Janssen
|
Charles Hicks, MD
- Contracted Research: Argos; BMS; Gilead; Janssen; Merck; ViiV
- Consulting Fees: BMS; Gilead; Janssen; Merck; ViiV
|
Paul Sax, MD
- Contracted Research: BMS; Gilead; Merck; GSK; Tibotec
- Consulting Fees: Abbott; BMS; GSK; Gilead; Tibotec; Merck
|
David Wohl, MD
- Contracted Research: GSK; Merck
- Consulting Fees: Gilead; Tibotec
|
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following planners and managers, Jan Hixon, RN, BSN, MA; Trace Hutchinson, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Back to Top
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine (PIM), ViralEd, Inc. and Gilead Sciences. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the, PIM, ViralEd, Inc. and Gilead Sciences. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Back to Top
Instructions for Participation and Credit
There are no fees for participating and receiving credit for this activity. During the period, November 18, 2011 through November 18, 2012 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and evaluation form.
To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on the Submit Post-test at the bottom of the page. Your post-test will automatically be graded.
If you successfully complete the post-test (score of 70% or higher). your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you received a score of 69% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.
You may complete the post-test online at: www.cmeuniversity.com
Click on "Find Post-Test/Evaluation by Course" on the navigation menu
Search by project ID: 8256
Upon successfully completing the Post-test and Evaluation form, your certificate will be made available immediately
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Back to Top
Supported by an unrestricted educational grant from Gilead Sciences.
|